No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients

Leuk Lymphoma. 2019 Nov;60(11):2798-2801. doi: 10.1080/10428194.2019.1602264. Epub 2019 May 6.

Authors

Lasse Hjort Jakobsen^{1

2}, Jorne Lionel Biccler^{1

2}, Peter de Nully Brown³, Judit Mészáros Jørgensen⁴, Pär Lars Josefsson⁵, Christian Bjørn Poulsen⁶, Jørn Starklint⁷, Michael Roost Clausen⁸, Per Trøllund Pedersen⁹, Maja Bech Juul¹⁰, Marianne Tang Severinsen^{1

2}, Martin Bøgsted^{1

2}, Tarec Christoffer El-Galaly^{1

2}

Affiliations

¹ Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
² Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
³ Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
⁴ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
⁵ Department of Hematology, Herlev Hospital, Herlev, Denmark.
⁶ Department of Hematology, Roskilde Sygehus, Roskilde, Denmark.
⁷ Department of Medicine, Hospitalsenheden Vest, Holstebro, Denmark.
⁸ Department of Hematology, Vejle Sygehus, Vejle, Denmark.
⁹ Department of Hematology, Sydvestjysk Sygehus, Esbjerg, Denmark.
¹⁰ Department of Hematology, Odense University Hospital, Odense, Denmark.

PMID: 31057011
DOI: 10.1080/10428194.2019.1602264

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use*
Dänemark
Female
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / mortality*
Lymphoma, Large B-Cell, Diffuse / pathology
Male
Middle Aged
Prognosis
Rituximab / therapeutic use*
Young Adult

Substances

Antineoplastic Agents, Immunological
Rituximab